Menu Back to Real-World-Evidence-Conference


October 16-17: Conference

In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is becoming increasingly important for regulatory and reimbursement decision-making. Historically used for post-market safety monitoring, RWE is now integrated throughout the product development lifecycle, and has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions.

DIA’s Real-World Evidence Conference will explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making.

While we develop our 2023 agenda, please take a moment to review the 2022 final agenda.

Participant Testimonials

“DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees.” - Nicholaas Honig, JD, Associate Regulatory Counsel, Aetion

Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Today’s Baltimore is a place where good ideas and ambition are the currency that matter most. It’s a place where art is seen as a catalyst for conversation, food as a means of connection, and history as an opportunity for education. It’s an essential destination full of inclusive neighborhoods where all visitors will feel invited, welcomed, and seen. Click here to check out all the tour guides based on your interests.

Register Today


Want to learn more about Real-World Evidence Conference? You've come to the right site!
DIA Global Annual Meeting


View our Exhibit Partners and explore our latest offerings

Learn more
Generic Highlights

Highlights & Features

Stay in the know with what's going on at the event

Learn more

Who should attend?

Join professionals from every corner of the vast realm of real-world data and real-world evidence:

  • Academia
  • Clinical Research
  • Data analytics
  • Epidemiology
  • Health Economics and Outcomes Research
  • Pharmacovigilance
  • Policy
  • Real-World Evidence
  • Real-World Data
  • Regulatory Science
  • Technology development

Program Committee

  • David  Martin, MD, MPH
    David Martin, MD, MPH Vice President, Global Head RWE, Medical Affairs
    Moderna, United States
  • John  Concato, MD, MPH, MS
    John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
    FDA, United States
  • Simon  Dagenais, PhD, MSc
    Simon Dagenais, PhD, MSc Senior Director, RWE Center of Excellence
    Pfizer Inc, United States
  • Rachele  Hendricks-Sturrup, DrSc, MA, MSc
    Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
    Duke-Robert J. Margolis, MD, Center for Health Policy, United States
  • Brad  Jordan, PhD
    Brad Jordan, PhD Senior Director, Head of Regulatory Affairs Policy
    Flatiron Health, United States
  • Nirosha M. Lederer, PhD, MS
    Nirosha M. Lederer, PhD, MS Head, US Government Partnerships; Senior Director, RWE Strategy
    Aetion, United States
  • Charles  Lee, MBA, MS
    Charles Lee, MBA, MS Executive Regulatory Science Director
    AstraZeneca, United States
  • Yun  Lu, PhD, MS
    Yun Lu, PhD, MS Mathematical Statistician, Office of Biostatistics and Pharmacovigilance, CBER
    FDA, United States
  • Sarah  Martin, PhD, MS
    Sarah Martin, PhD, MS Senior Director, Science and Regulatory Advocacy
    PhRMA, United States
  • Brittany  McKelvey
    Brittany McKelvey Director, Regualtory Affairs
    Friends of Cancer Research, United States
  • Keri  Monda, PhD, MS
    Keri Monda, PhD, MS Executive Director, Center for Observational Research
    Amgen, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions